SE9802729D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE9802729D0
SE9802729D0 SE9802729A SE9802729A SE9802729D0 SE 9802729 D0 SE9802729 D0 SE 9802729D0 SE 9802729 A SE9802729 A SE 9802729A SE 9802729 A SE9802729 A SE 9802729A SE 9802729 D0 SE9802729 D0 SE 9802729D0
Authority
SE
Sweden
Prior art keywords
novel compounds
therapy
processes
preparation
pharmaceutical compositions
Prior art date
Application number
SE9802729A
Other languages
English (en)
Swedish (sv)
Inventor
Andrew Baxter
Elizabeth Kinchin
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9802729A priority Critical patent/SE9802729D0/xx
Publication of SE9802729D0 publication Critical patent/SE9802729D0/xx
Priority to ES99943554T priority patent/ES2190246T3/es
Priority to NZ509457A priority patent/NZ509457A/xx
Priority to DE69905170T priority patent/DE69905170T2/de
Priority to PCT/SE1999/001333 priority patent/WO2000009511A1/en
Priority to EP99943554A priority patent/EP1104425B1/en
Priority to DK99943554T priority patent/DK1104425T3/da
Priority to AT99943554T priority patent/ATE231872T1/de
Priority to JP2000564962A priority patent/JP4612189B2/ja
Priority to CA002338600A priority patent/CA2338600C/en
Priority to AU56625/99A priority patent/AU768004B2/en
Priority to US09/403,392 priority patent/US6806273B1/en
Priority to JP2010110322A priority patent/JP2010168405A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9802729A 1998-08-13 1998-08-13 Novel Compounds SE9802729D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9802729A SE9802729D0 (sv) 1998-08-13 1998-08-13 Novel Compounds
US09/403,392 US6806273B1 (en) 1998-08-13 1999-08-03 Compounds
PCT/SE1999/001333 WO2000009511A1 (en) 1998-08-13 1999-08-03 Novel thiazolopyrimidine compounds
NZ509457A NZ509457A (en) 1998-08-13 1999-08-03 Thiazolopyrimidine compounds suitable for the treatment of inflammatory disorders
DE69905170T DE69905170T2 (de) 1998-08-13 1999-08-03 Thiazolopyrimidinderivate
ES99943554T ES2190246T3 (es) 1998-08-13 1999-08-03 Nuevos compuestos de tiazolopirimidina.
EP99943554A EP1104425B1 (en) 1998-08-13 1999-08-03 Novel thiazolopyrimidine compounds
DK99943554T DK1104425T3 (da) 1998-08-13 1999-08-03 Hidtil ukendte thiazolopyrimidinforbindelser
AT99943554T ATE231872T1 (de) 1998-08-13 1999-08-03 Thiazolopyrimidinderivate
JP2000564962A JP4612189B2 (ja) 1998-08-13 1999-08-03 新規チアゾロピリミジン化合物
CA002338600A CA2338600C (en) 1998-08-13 1999-08-03 Novel thiazolopyrimidine compounds
AU56625/99A AU768004B2 (en) 1998-08-13 1999-08-03 Novel thiazolopyrimidine compounds
JP2010110322A JP2010168405A (ja) 1998-08-13 2010-05-12 新規チアゾロピリミジン化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802729A SE9802729D0 (sv) 1998-08-13 1998-08-13 Novel Compounds

Publications (1)

Publication Number Publication Date
SE9802729D0 true SE9802729D0 (sv) 1998-08-13

Family

ID=20412248

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802729A SE9802729D0 (sv) 1998-08-13 1998-08-13 Novel Compounds

Country Status (12)

Country Link
US (1) US6806273B1 (xx)
EP (1) EP1104425B1 (xx)
JP (2) JP4612189B2 (xx)
AT (1) ATE231872T1 (xx)
AU (1) AU768004B2 (xx)
CA (1) CA2338600C (xx)
DE (1) DE69905170T2 (xx)
DK (1) DK1104425T3 (xx)
ES (1) ES2190246T3 (xx)
NZ (1) NZ509457A (xx)
SE (1) SE9802729D0 (xx)
WO (1) WO2000009511A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
WO2001058906A1 (en) * 2000-02-11 2001-08-16 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
HUP0300754A3 (en) * 2000-07-18 2009-03-02 Smithkline Beecham Corp Use of il-8 receptor antagonists in the treatment of virus infections
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
ES2295685T3 (es) * 2002-08-24 2008-04-16 Astrazeneca Ab Derivados de pirimidina como moduladores de la actividad del receptor de quimioquinas.
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US20070142386A1 (en) * 2003-10-07 2007-06-21 Astrazeneca New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
ES2442678T3 (es) 2004-08-28 2014-02-12 Astrazeneca Ab Derivados de pirimidín sulfonamidas como moduladores del receptor de quimioquina
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
JP2008524186A (ja) * 2004-12-17 2008-07-10 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物
UA90707C2 (xx) * 2005-04-06 2010-05-25 Астразенека Аб 5-ЗАМІЩЕНІ ПОХІДНІ 7-АМІНО-$1,3]ТІАЗОЛО$4,5-d]ПІРИМІДИНУ$5-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 7-АМИНО-$1,3]ТИАЗОЛО$4,5-d]ПИРИМИДИНА
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
NZ576519A (en) * 2006-09-29 2011-11-25 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5-d] pyrimidin-2 (3h)-amine derivatives and their use in therapy
WO2008094662A2 (en) 2007-02-01 2008-08-07 Interdigital Technology Corporation Method and apparatus for supporting rlc re-segmentation
BRPI0908529A2 (pt) * 2008-02-26 2015-09-29 Novartis Ag composto orgânicos
WO2010142027A1 (en) * 2009-06-12 2010-12-16 Socpra - Sciences Et Genie S. E. C. Guanine riboswitch binding compounds and their use as antibiotics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB713652A (en) * 1951-06-04 1954-08-18 Wellcome Found Improvements in or relating to heterocyclic compounds and their manufacture
BE543978A (xx) 1955-01-03
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
JP2002510695A (ja) * 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン

Also Published As

Publication number Publication date
ATE231872T1 (de) 2003-02-15
DK1104425T3 (da) 2003-06-23
NZ509457A (en) 2002-07-26
JP2002522544A (ja) 2002-07-23
ES2190246T3 (es) 2003-07-16
WO2000009511A1 (en) 2000-02-24
US6806273B1 (en) 2004-10-19
CA2338600C (en) 2008-01-08
AU5662599A (en) 2000-03-06
DE69905170T2 (de) 2004-01-15
AU768004B2 (en) 2003-11-27
CA2338600A1 (en) 2000-02-24
JP4612189B2 (ja) 2011-01-12
DE69905170D1 (en) 2003-03-06
JP2010168405A (ja) 2010-08-05
EP1104425B1 (en) 2003-01-29
EP1104425A1 (en) 2001-06-06

Similar Documents

Publication Publication Date Title
SE9802729D0 (sv) Novel Compounds
SE9704546D0 (sv) Novel compounds
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
TR200100054T2 (tr) Paroksetin metansülfonat
SE9704544D0 (sv) Novel compounds
TR200001203T2 (tr) Yeni birleşik maddeler
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
GB0004128D0 (en) Novel compounds
TW200505875A (en) Novel compounds
TR200000152T2 (tr) Yeni bileşikler.
YU13301A (sh) Muskarinski agonisti i antagonisti
SE9802937D0 (sv) Novel compounds
SE9904377D0 (sv) Pharmaceutical combinations
SE0102716D0 (sv) Novel compounds
SE9801494D0 (sv) Novel use
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
ATE28188T1 (de) Antikonvulsive mittel.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
NO20005548L (no) Mykobakterieinhibitorer
NZ217356A (en) Benzamide derivatives and pharmaceutical compositions
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao